Compare GameStop Corp. (GME) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs TransMedics Group Inc — how do they compare? GameStop Corp. trades at $26.6 (market cap $12.75B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: GameStop Corp. is far larger — about 4.7× TransMedics Group Inc's market cap, and GameStop Corp. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and TransMedics Group Inc for 24 Days on average.
| GME | TMDX | |
|---|---|---|
Market Cap | $12.75B | $2.74B |
Volume | 13,026,993 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $150.42 |
52-Week Low | $17.87 | $61.99 |
Typical Hold Time | 62 Days | 24 Days |
Enterprise Value | $12.03B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GameStop (GME) trades at $26.37, up 7.28% in 24 hours, with a bullish technical signal and strong insider buying by CEO Ryan Cohen. The company reported net income of $131.3 million in 2025, a significant turnaround from prior losses, though revenue declined to $3.82 billion. Valuation ratios include a P/E of 16.63 and P/S of 4.22, while analyst consensus remains mixed with 16.67% buy ratings.
The outlook hinges on sustained profitability and strategic shifts, but risks include revenue volatility and competitive pressures. Insider confidence provides near-term support, yet the stock faces headwinds from cautious Wall Street sentiment and execution challenges in a declining physical retail environment.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
